Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 ‘Stivarga more potent in improving Asian patients’ survival’
2 Stivarga, Opdivo have similar survival outcomes in HCC
3 Stivarga and Opdivo Provide Comparable Survival Benefits for People With Liver Cancer
4 Bayer to Showcase New Data from Evolving Oncology Portfolio at ESMO Virtual Congress 2020
5 Bayer to Present New Data from Evolving Oncology Portfolio at ESMO 2020
6 Colorectal Cancer Treatment Continues to Be Personalized
7 First Patient Dosed in Trial of CS1001 Plus Stivarga for Advanced Tumors
8 Real-World Study Confirms Safety of Regorafenib After Sorafenib in Unresectable HCC
9 I'm battling Stage 4 colon cancer: Chadwick Boseman's secret fight stuns me
10 FDA expands approved use of Stivarga to treat liver cancer
11 Blueprint's Ayvakit fails to best Bayer's Stivarga
12 Bayer, Apotex Settle Patent Suit on Stivarga Cancer Drug
13 Cabometyx superior to Stivarga as second-line liver cancer treatment
14 Immunicum AB (publ) Announces Publication of Abstract for the ESMO Virtual Congress 2020
15 Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
16 Bayer's dominance in liver cancer challenged
17 Can Stivarga crack the code? Bayer hunts for rare glioblastoma nod with 'Big 5' contender
18 Dr. Grothey on Choosing Between Regorafenib and TAS-102 in mCRC
19 Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
20 Dr. Lenz on Optimal Sequencing Strategies in CRC
21 Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
22 Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
23 Peripheral neuropathy reported in liver cancer drug Stivarga
24 Stivarga to be tested as therapy for glioblastoma
25 Bayer's Stivarga wins NICE backing for advanced liver cancer
26 Continued PFS, OS Benefit Seen With Ripretinib in Advanced GIST
27 NICE turns down Bayer's Stivarga for liver cancer
28 Bayer's struggling Stivarga moves closer to liver-cancer lifeline with FDA 'priority' tag
29 EMA clears Bayer's Stivarga for liver cancer
30 Cabozantinib May Be a Match for Regorafenib in Second line Advanced HCC
31 Nivolumab Plus Regorafenib Regimen Active in Gastrointestinal Cancers
32 Bayer eyes liver cancer indication for Stivarga
33 Stivarga final NICE recommendation for hepatocellular carcinoma
34 FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors
35 Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC
36 Regorafenib Plus TAS-102 Demonstrates Clinically Meaningful Disease Control in mCRC
37 Bayer's growth-driving quintet? Better make it a trio, thanks to Stivarga and Xofigo stall
38 Blueprint's Ayvakit gets FDA no-go in new stomach cancer use but presses ahead in blood disorder
39 Liver cancer patients barred from NHS access to Bayer's Stivarga
40 NICE backing for Bayer's Stivarga in GIST
41 Bayer's Stivarga OK'd for Colon Cancer
42 Exploring Regorafenib and Nivolumab as Treatment for Colorectal Cancer
43 Comparing Stivarga and Lonsurf in Metastatic Colorectal Cancer
44 Bayer's Stivarga improves liver cancer survival rates, trial shows
45 Dr. Lenz on Later-Line Combo Approaches in CRC
46 Dr. Halfdanarson on Investigational Agents in Driver-Negative CRC
47 Sequencing Challenges Impact the Management of Advanced Hepatocellular Carcinoma
48 Coronavirus compounds trouble for Bayer
49 Bayer's Stivarga First Drug To Enter Brain Cancer Platform Trial
50 Bayer's Stivarga® (regorafenib) Tablets Approved by US FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST
51 Dr. Cusnir on the Utility of Regorafenib in Gastric Cancer
52 FDA Approves New Treatment for Advanced Colorectal Cancer
53 Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
54 NICE recommends Stivarga ® for advanced unresectable HCC
55 Bayer's Stivarga Patent Challenged in Inter Partes Review
56 STIVARGA (Regorafenib) For Patients with Unresectable Hepatocellular Carcinoma
57 Bayer, BMS, Ono team up to investigate Stivarga, Opdivo combo
58 CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
59 Bayer takes giant colon on tour to drum up colorectal cancer awareness
60 What Is the Best Treatment Option for Advanced Colorectal Cancer?
61 Bayer gets new Japanese approval for Stivarga
62 Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials
63 Regorafenib/Nivolumab Combo to Be Studied in Phase III Trial of Patients With MSS mCRC
64 U.S. cancer doctors drop pricey drugs with little or no effect
65 Bayer's Stivarga races to FDA approval on the heels of Zaltrap
66 Real-Life Analysis of Nivolumab in Patients With HCC Align With Clinical Trial Data
67 Regorafenib/TAS-102 Induces Clinically Meaningful DCR in Refractory Metastatic CRC
68 Bayer's Stivarga® (regorafenib) Tablets Approved in Japan
69 Immunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO Congress
70 Combination of Durvalumab and Tremelimumab May Prolong OS in CRC
71 Individualized Treatment Is Key for mCRC
72 UPDATED: Bayer counts on Nexavar-Stivarga 'continuum' to protect its liver-cancer lead
73 Bayer wins GIST approval for Stivarga in EU
74 Blueprint beats Deciphera to the punch
75 Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
76 Metastatic Colorectal Cancer Treatments Continue to Change
77 Bayer to Highlight Latest Stivarga® (regorafenib) Tablets Research at ASCO GI 2016
78 RESORCE Trial Analysis Shows Higher AFP Responses Achieved With Regorafenib in HCC
79 FDA clears Blueprint's $32k-per-month GI cancer drug
80 Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug
81 New Insight into Colorectal Cancer Could Lead to New Therapies
82 Bristol Myers scores new FDA nod for Opdivo/Yervoy combo; US Army wants Gilead's potential Covid-19 drug for infected troops
83 Regorafenib dosing strategies reduce adverse events among patients with colorectal cancer
84 Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy
85 Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial
86 Blueprint’s voyage ends in disaster
87 Disease Control Achieved With Regorafenib in Refractory GIST Using Reduced, Continuous Dosing
88 Novel Strategies Progress Through mCRC Pipeline
89 Seoul accepts Bayer’s request to reduce study subjects of cancer drug
90 Qinlock Approved for Fourth-Line Treatment of GIST
91 Combo Improves Survival in Refractory Colorectal Cancer
92 Regorafenib Plus Nivolumab Limits Tumor Growth In Gastric and Colorectal Cancers
93 Bayer, facing more Roundup suits, yields to shareholder request for M&A review
94 Expert Explores Second-Line Treatment Options for Hepatocellular Carcinoma
95 FDA Will Split NDA For Avapritinib Into Two Separate Submissions
96 Regorafenib/Nivolumab Combo to Be Explored in Phase III MSS CRC Trial
97 Dose-Optimization Strategies Continue for Regorafenib in Colorectal Cancer With ReDOS Success
98 Real-Life Analysis Confirms Benefit of Sorafenib/Regorafenib Sequence in HCC
99 The Science Leading to Robust Responses in MSI-High Mismatch Repair Deficient mCRC in CheckMate 142
100 Ripretinib Approval Advances Recurrent GIST Paradigm